MicroRNA-372 is associated with poor prognosis in colorectal cancer

Oncology

Volumn 82, Issue 4, 2012, Pages 205-212

  Yamashita, Shinya ^a   Yamamoto, Hirofumi ^a   Mimori, Koshi ^b   Nishida, Naohiro ^b   Takahashi, Hidekazu ^a   Haraguchi, Naotsugu ^a   Tanaka, Fumiaki ^b   Shibata, Kohei ^b   Sekimoto, Mitsugu ^a   Ishii, Hideshi ^a   Doki, Yuichiro ^a   Mori, Masaki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Colon cancer; LATS2; Liver metastasis; MicroRNA; Prognosis

Indexed keywords

LARGE TUMOR SUPPRESSOR 2; MICRORNA; MICRORNA 372; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MICRORNAS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84858963072     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000336809     Document Type: Article

References (40)

1. Tenesa A, Dunlop MG: New insights into the aetiology of colorectal cancer from genomewide association studies. Nature Reviews Genetics 2009; 10: 353-358.
2. Kotake K, Honjo S, Sugihara K, Kato T, Kodaira S, Takahashi T, Yasutomi M, Muto T, Koyama Y: Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan. Dis Colon Rectum 2003; 46:S32-S43. (Pubitemid 37270589)
3. Saltz LB, Clarke S, Daz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
4. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. NEJM 2004; 351: 337-345. (Pubitemid 38944402)
5. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
6. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA: MicroRNAs -the micro steering wheel of tumour metastases. Nat Rev Cancer 2009; 9: 293-302.
7. Spizzo R, Nicoloso MS, Croce CM, Calin GA: SnapShot: microRNAs in Cancer. Cell 2009; 137: 586-586.e1.
8. Waldman SA, Terzic A: Translating Micro-RNA discovery into clinical biomarkers in cancer. JAMA 2007; 297: 1923-1925. (Pubitemid 46707848)
9. Nagel R, le Sage C, Diosdado B, van der Waal M, Oude Vrielink JAF, Bolijn A, Meijer GA, Agami R: Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res 2008; 68: 5795-5802.
10. Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung JJ, Kwok TT: Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 2010; 31: 350-358.
11. Duale N, Lindeman B, Komada M, Olsen AK, Andreassen A, Soderlund EJ, Brunborg G: Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles. Mol Cancer 2007; 6: 53.
12. Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T: Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 2010; 79: 313-320.
13. Voorhoeve PM, le Sage C, Schrier M, Gillis AJM, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A: A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006; 124: 1169-1181.
14. Cho WJ, Shin JM, Kim JS, Lee MR, Hong KS, Lee JH, Koo KH, Park JW, Kim KS: miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2. Mol Cells 2009; 28: 521-527.
15. Tian RQ, Wang XH, Hou LJ, Jia WH, Yang Q, Li YX, Liu M, Li X, Tang H: Micro-RNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis. J Biol Chem 2011; 286: 25556-25563.
16. Sobin LH, Fleming ID: TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997; 80: 1803-1804.
17. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93: 387-391. (Pubitemid 43080010)
18. Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y, Mori M: MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res 2011; 17: 2725-2733.
19. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta] CT method. Methods 2001; 25: 402-408. (Pubitemid 34164012)
20. Mori M, Mimori K, Yoshikawa Y, Shibuta K, Utsunomiya T, Sadanaga N, Tanaka F, Matsuyama A, Inoue H, Sugimachi K: Analysis of the gene-expression profile regarding the progression of human gastric carcinoma. Surgery 2002; 131:S39-S47. (Pubitemid 34118615)
21. Utsunomiya T, Okamoto M, Hashimoto M, Yoshinaga K, Shiraishi T, Tanaka F, Mimori K, Inoue H, Watanabe G, Barnard GF: A gene-expression signature can quantify the degree of hepatic fibrosis in the rat. J Hepatol 2004; 41: 399-406. (Pubitemid 39158749)
22. Ogawa K, Utsunomiya T, Mimori K, Tanaka F, Inoue H, Nagahara H, Murayama S, Mori M: Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res 2005; 11: 2889-2893. (Pubitemid 40525189)
23. Yamamoto H, Kondo M, Nakamori S, Nagano H: JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis. Gastroenterology 2003; 125: 556-571. (Pubitemid 36929437)
24. Uemura M, Ikeda M, Yamamoto H, Kitani K, Tokuoka M, Matsuda K, Hata Y, Mizushima T, Takemasa I, Sekimoto M: Clinicopathological assessment of locally recurrent rectal cancer and relation to local re-recurrence. Ann Surg Oncol 2011; 18: 1015-1022.
25. Miyoshi N, Ishii H, Nagano H, Haraguchi N, Dewi DL, Kano Y, Nishikawa S, Tanemura M, Mimori K, Tanaka F: Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 2011; 8: 633-638.
26. Subramanyam D, Lamouille S, Judson RL, Liu JY, Bucay N, Derynck R, Blelloch R: Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol 2011; 29: 443-448.
27. Kamikubo Y, Takaori-Kondo A, Uchiyama T, Hori T: Inhibition of cell growth by conditional expression of kpm, a human homologue of Drosophila warts/lats tumor suppressor. J Biol Chem 2003; 278: 17609-17614. (Pubitemid 36799362)
28. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T: p27 expression and gastric carcinoma. Nat Med 1997; 3: 593.
29. Karamitopoulou E, Zlobec I, Koumarianou A, Patsouris ES, Peros G, Lugli A: Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups. Cancer 2010; 116: 4474-4486.
30. Sarkar R, Hunter I, Rajaganeshan R, Perry S, Guillou P, Jayne D: Expression of cyclin D2 is an independent predictor of the development of hepatic metastasis in colorectal cancer. Colorectal Dis 2010; 12: 316-323.
31. Takemasa I, Yamamoto H, Sekimoto M, Ohue M, Noura S, Miyake Y, Matsumoto T, Aihara T, Tomita N, Tamaki Y: Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. Cancer Res 2000; 60: 3043-3050. (Pubitemid 30395833)
32. Betel D, Wilson M, Gabow A, Marks DS, Sander C: The microRNA.org resource: targets and expression. Nucleic Acids Res 2008; 36:D149-D153. (Pubitemid 351149712)
33. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, Noguchi S: Downregulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 2005; 11: 1380-1385. (Pubitemid 40315216)
34. Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH: Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep 2009; 22: 1519-1526.
35. Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G, Lu D: Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res 2006; 56: 450-458. (Pubitemid 44750270)
36. Ciaparrone M, Yamamoto H, Yao Y, Sgambato A, Cattoretti G, Tomita N, Monden T, Rotterdam H, Weinstein IB: Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. Cancer Res 1998; 58: 114.
37. Yamamoto H, Soh JW, Monden T, Klein MG, Zhang LM, Shirin H, Arber N, Tomita N, Schieren I, Stein C: Paradoxical increase in retinoblastoma protein in colorectal carcinomas may protect cells from apoptosis. Clin Cancer Res 1999; 5: 1805-1815. (Pubitemid 29334462)
38. Gope R, Christensen MA, Thorson A, Lynch HT, Smyrk T, Hodgson C, Wildrick DM, Gope ML, Boman BM: Increased expression of the retinoblastoma gene in human colorectal carcinomas relative to normal colonic mucosa. J Natl Cancer Inst 1990; 82: 310-314. (Pubitemid 20097705)
39. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997; 3: 231-234. (Pubitemid 27064711)
40. Weinstein IB: Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 2000; 21: 857-864. (Pubitemid 30265126)